Maxim Group analyst Anthony Vendetti maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and l

Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowe

BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million t

BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences NASDAQ: BHST reported second-quarter 2026 revenue of $8.8 million, up 3.8% from

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported higher second-quarter revenue as the plant-

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks C

BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business

Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production prog

This particular scent is widely regarded as one of the most valuable fragrance raw materials in the

Exclusive agreement through 2027 and 2028 is estimated to generate $20-$30 million in revenue Positi

Nu Skin Enterprises (NYSE: NUS - Get Free Report) and BioHarvest Sciences (NASDAQ: BHST - Get Free R

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Scien

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Scien

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has received a 4.33 million NIS

BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and su

Grant will partially fund research to enable faster development, with a higher probability of succes

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Scien

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Scien

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration wit

The expanded collaboration builds on the initial agreement signed in 2024 and reflects strong techni

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening sol

BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript

BioHarvest Sciences NASDAQ: BHST reported higher first-quarter revenue and reiterated its 2026 outlo

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.11 per share versus the Zacks C

BioHarvest Sciences (NASDAQ:BHST) affirms FY2026 sales outlook from $42.000 million-$48.000 million

BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.11) per share

Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDM

- CDMO program advances to Stage 2 of development agreement valued at $1.125 million-Advancement of

BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"),

BioHarvest Sciences (NASDAQ:BHST) sees FY2026 sales of $42.000 million-$48.000 million vs $48.432 mi

BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.10) per share

With Stage 1 now completed, BioHarvest is ready to advance to Stage 2, where cells stored in a propr

Roth Capital analyst Sean McGowan initiates coverage on BioHarvest Sciences (NASDAQ:BHST) with a

BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"),

BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"),

BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.14) per share

BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"),